Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L. Alves, Henrik J. Ditzel|Nature Communications|2021Cited by 82
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancerCharlotte K. Kindt, Carla L. Alves|Frontiers in Oncology|2025Cited by 1